(Press-News.org) Contact information: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center
Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
Phase III trial examines pathological complete response rate
HOUSTON — Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research from Aman Buzdar M.D., professor and vice president of clinical research at The University of Texas MD Anderson Cancer Center, and colleagues in the Alliance for Clinical Trials in Oncology, shows these agents do not need to be given concurrently to achieve a high rate of complete pathological remission.
The findings, published in the journal Lancet Oncology, investigated the timing of trastuzumab administration with anthracycline and taxane chemotherapy.
"In a previous MD Anderson study concurrent administration of trastuzumab with chemotherapy, including anthracyclines, demonstrated high pathologic complete response rates in breast cancer patients with HER-2-positive disease," Buzdar said. "In the current trial, we examined whether concurrent administration of anthracyclines with trastuzumab was necessary to achieve the high pathologic response rates or whether these drugs could be given sequentially. Findings show that high pathologic response rates were observed in both treatment groups with similar cardiac safety profiles in both arms of the trial."
The randomized phase III trial enrolled 280 women with operable HER-2 positive invasive breast cancer at 36 centers across the United States from September 2007 through December 2011.
Patients were randomly assigned to two treatment regimens, 138 in the sequential group who received fluorouracil, epirubicin and cyclophosphamide on day one of a 21-day cycle for four cycles followed by paclitaxel plus trastuzumab weekly for 12 weeks.
The 142 patients in the concurrent group were treated with paclitaxel and trastuzumab weekly for 12 weeks. This was followed by fluorouracil, epirubicin and cyclophosphamide on day one of a 21-day cycle with trastuzumab on days one, eight and 15 of the 21-day cycle for four cycles.
Each patient in both arms of the trial received a total of one year of trastuzumab therapy. The primary endpoint of the trial was the proportion of patients who had pathological complete remission in the breast, defined as the percentage of women who started the neoadjuvant treatment with no histological evidence of disease in the breast at surgery.
"If a patient achieves complete pathological remission, we know from previous experience that more than 90 percent continue to remain free of their disease at longer follow-up," Buzdar said, who also served as the principal investigator of the trial.
Similar responses seen in both treatment groups
The findings showed that 56.5 percent of patients in the sequential group had a complete pathological remission versus 54.2 percent of the patients who received the concurrent regimen, a difference that was not significant.
Next Steps
Researchers are now in the process of analyzing the genomic profiles of the breast tumors that were obtained during the trial to better understand patient responses. The purpose is to evaluate the specific characteristics of a tumor that is sensitive to these therapies, as well as identify the profiles that are resistant.
Kelly Hunt, M.D., professor in MD Anderson's Department of Surgical Oncology and co-principle investigator of the trial, said if we can identify the patients most likely to have pathologic complete response with therapy, we can reduce or potentially eliminate surgery for these patients in the future.
###
This research was supported by the National Cancer Institute grant U10 CA76001 to the American College of Surgeons Oncology Group and the National Cancer Institute to the Alliance for Clinical Trials in Oncology CA33601.
In addition to Buzdar, other MD Anderson authors include: Kelly Hunt, M.D., Funda Meric-Bernstam, M.D., and Michael Ewer, M.D. Other authors include: Marilyn Leitch, M.D., The University of Texas Southwestern Medical Center, Matthew Ellis, Ph.D., Washington University School of Medicine in St. Louis, Judy Boughey, M.D., The Mayo Clinic, Gary Unzeitig, M.D., Doctors Hospital of Laredo Texas, Melanie Royce, M.D., Ph.D., University of New Mexico Cancer Center and Linda McCall, Duke Cancer Institute.
The Alliance for Clinical Trials in Oncology is a clinical trials network sponsored by the National Cancer Institute that consists of nearly 10,000 cancer specialists at hospitals, medical centers and community clinics across the country and Canada. The Alliance is dedicated to developing and conducting clinical trials with promising new cancer therapies and utilizes the best science to develop optimal treatment and prevention strategies for cancer, as well as researching methods to alleviate side effects of cancer and cancer treatments.
Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
Phase III trial examines pathological complete response rate
2013-11-13
ELSE PRESS RELEASES FROM THIS DATE:
Parental monitoring lowers odds of a gambling problem
2013-11-13
Parental monitoring lowers odds of a gambling problem
Parental supervision at ages 11-14 lowers risk for problem gambling by age 22
November 12, 2013—Keeping an eye on your child can lower their odds for gambling by young adulthood, ...
Bring a 50,000-degree plasma into your living room
2013-11-13
Bring a 50,000-degree plasma into your living room
An online open-user experiment puts users in control of a real physics laboratory
With the rise of online open course platforms such as Khan Academy, MIT OpenCourseWare and iTunes U, it has never been easier to ...
NASA sees Veteran's Day solar flare
2013-11-13
NASA sees Veteran's Day solar flare
The sun emitted a significant solar flare that peaked at 12:14 a.m. EST on Nov. 10, 2013. Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth's atmosphere ...
Structure of bacterial nanowire protein hints at secrets of conduction
2013-11-13
Structure of bacterial nanowire protein hints at secrets of conduction
Electrically conducting bacteria important for energy, environment and technology
RICHLAND, Wash. -- Tiny electrical wires protrude from some bacteria and contribute to ...
Riding an electron wave into the future of microchip fabrication
2013-11-13
Riding an electron wave into the future of microchip fabrication
Computer simulation explores how intense plasma waves generate suprathermal electrons, which are critical to microchip fabrication
Advanced plasma-based etching is a key enabler of Moore's Law that ...
Putting a new spin on tokamak disruptions
2013-11-13
Putting a new spin on tokamak disruptions
Rapid plasma rotation may be the key to softening the blow of powerful plasma disruptions
In the quest for fusion energy on earth, researchers use magnetic fields to insulate hot plasma from the walls of the chamber to ...
Researcher finds potential new use for old drugs
2013-11-13
Researcher finds potential new use for old drugs
From malaria to cancers and immune-related diseases
PULLMAN, Wash. – A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led ...
Our relationship with food: What drives us to eat and new insights into eating disorders
2013-11-13
Our relationship with food: What drives us to eat and new insights into eating disorders
New treatments for binge eating, how our diet impacts brain function, and the connection between marijuana and obesity
SAN DIEGO — A growing body of evidence shows the impact of ...
Stepparents are not always evil
2013-11-13
Stepparents are not always evil
Parents' strategy to love their children depends on more than blood ties
Contrary to common belief, parents do not generally treat their stepchildren less favourably than their own. Until now, many researchers believed ...
No hot flashes? Then don't count on hormones to improve quality of life
2013-11-13
No hot flashes? Then don't count on hormones to improve quality of life
CLEVELAND, Ohio (November 13, 2013)—Hormones at menopause can help with sleep, memory, and more, but only when a woman also has hot flashes, find researchers ...
LAST 30 PRESS RELEASES:
AI detects fatty liver disease with chest X-rays
KIST develops high-performance memory devices that dissolve in water, addressing the E-waste problem
Tiny ocean migrants play a massive role in Southern Ocean carbon storage
Leafy greens could be good for the heart
How AI is making 2D materials stronger: An AI-driven framework to improve material design
Cascading impacts of groundwater input to coral reefs
Finding the enzymatic needle in the database haystack
In-line NMR guides orthogonal transformation of real-life plastics
Neopred: A dual-phase CT AI tool for preoperative prediction of pathological response in NSCLC
Discovery of ‘mini halo’ points to how the early universe was formed
Attention scan: How our minds shift focus in dynamic settings
Do you have a nosy coworker? BU research finds snooping colleagues send our stress levels rising
Research explores human factors in general aviation plane crashes
Study reveals mechanisms behind common mutation and prostate cancer
Beyond the big leagues: Concussion care in community sports
Further insights into the consequences of abnormal chromosome numbers
UC Irvine-led team uncovers cell structures that squids use to change their appearance
New research explores how food insecurity affects stress and mental health
New study confirms that the oldest rocks on Earth are in northern Canada
Study finds link between brain injury and criminal behavior
New research aims to better predict and understand cascading land surface hazards
Deeper sleep is more likely to lead to eureka moments
Hadean-age rocks preserved in the Nuvvuagittuq Greenstone Belt, Canada
Novel “digital fossil-mining” approach uncovers hidden fossils, revealing squids’ ancient origins
Review: New framework needed to assess complex “cascading” natural hazards
Flipping an evolutionarily disabled switch unlocks ear tissue regeneration in mice
Ancient squids dominated the ocean 100 million years ago
Public attitudes around solar geoengineering become less politically partisan with more familiarity
COVID-19 pandemic significantly eroded American public’s trust in US public health institutions like the CDC, shows longitudinal assessment from 2020-2024
Extreme droughts in LMICs are associated with increased sexual violence against girls and young women
[Press-News.org] Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancerPhase III trial examines pathological complete response rate